AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sachin Jain from Bank of America Securities reiterated a Buy rating on the stock and has a p14,500.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sachin Jain has given his Buy rating due to a combination of factors that highlight AstraZeneca’s strong position and future potential. The company’s recent investor call was reassuring, particularly on the topics of oncology and tariffs. AstraZeneca has established a new baseline for volume growth in its oncology division, and it appears well-prepared to manage any potential tariff impacts due to its strategic manufacturing locations.
Sachin Jain also points to AstraZeneca’s promising pipeline, which is expected to contribute significantly to future sales growth. The valuation of AstraZeneca’s stock is seen as attractive, with a mid-term guidance suggesting high-single-digit sales growth. Upcoming data releases from key trials, such as AVANZAR and SERENA-6, are anticipated to be transformative, potentially unlocking substantial sales opportunities. These elements, combined with a stable earnings outlook, underpin Jain’s confidence in AstraZeneca’s stock performance.
In another report released yesterday, Bernstein also maintained a Buy rating on the stock with a £172.00 price target.
AZN’s price has also changed slightly for the past six months – from p11534.000 to p10618.000, which is a -7.94% drop .